RETAPAMULIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H47NO4S
Molecular Weight	517.763
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C(=O)CC[C@]13CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]4C[C@@H]5CC[C@H](C4)N5C

InChI

InChIKey=STZYTFJPGGDRJD-NHUWBDDWSA-N

InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22-,24-,26+,27+,28-,29+,30+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H47NO4S
Molecular Weight	517.763
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022055s002lbl.pdf

Retapamulin is a topical antibiotic which was approved by FDA (Altabax brand name) for the treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Retapamulin exerts its antibacterial action by binding to 50S subunit of the bacterial ribosome.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
70S ribosome 16 Target ID: CHEMBL2364096 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022055s002lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Impetigo due to Staphylococcus aureus 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022055s002lbl.pdf	Curative		Approved 8429	ALTABAX Approved Use ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Launch Date 2007
Impetigo due to Streptococcus pyogenes 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022055s002lbl.pdf	Curative		Approved 8429	ALTABAX Approved Use ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Launch Date 2007

C_max

Value	Dose	Co-administered	Analyte	Population
3.5 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18416589/	1 % 1 times / day multiple, topical dose: 1 % route of administration: Topical experiment type: MULTIPLE co-administered:		RETAPAMULIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
49.6 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18416589/	1 % 1 times / day multiple, topical dose: 1 % route of administration: Topical experiment type: MULTIPLE co-administered:		RETAPAMULIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
6% REVIEW https://pubmed.ncbi.nlm.nih.gov/18416589/	1 % 1 times / day multiple, topical dose: 1 % route of administration: Topical experiment type: MULTIPLE co-administered:		RETAPAMULIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1	Disc. AE: Skin irritation, Sensitization... AEs leading to discontinuation/dose reduction: Skin irritation (severe) Sensitization Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Sensitization	Disc. AE	1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1
Skin irritation	severe Disc. AE	1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 P-gp 1461	CYP3A5 395 CYP1A2 1054 CYP2C19 991 CYP2C8 693 P-gp 1537

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 1.1 uM]	unlikely (co-administration study) Comment: retapamulin inhibited CYP3A4 isoenzyme activity, IC50 ranged from 1.1 uM with midazolam to 6.2 uM with nifedipine; I/Ki ratios are less than 0.1 for all CYP P450 isoenzymes and no clinically relevant DDI are anticipated when retapamulin is coadministered with other drugs metabolized by CYPs Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5, 6	weak [IC50 28.2 uM]	unlikely (co-administration study) Comment: in vitro inhibitor of digoxin transport by P-gp with a calculated IC50 value of 28.2 uM; it is unlikely that retapamulin will inhibit P-gp mediated transport of co-administered drugs Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5, 6
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	weak [IC50 >99 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	major	yes (co-administration study) Comment: coadministration with ketaconazole increased retapamulin Cmax by 80% and AUC by 77% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	minor
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	no
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	no
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 5.0	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022055s000_ClinPharmR.pdf Page: 6.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0039HR	https://www.aablocks.com/goods/Goods/detail?id=AA0039HR
AEchem Scientific Corp., USA	AE1-017412	http://www.aechemsc.com/info_products/AE1-017412.php
AK Scientific, Inc. (AKSCI)	66719	http://www.aksci.com/item_detail.php?cat=66719
Aaron Chemicals	AR003A9J	http://www.aaronchem.com/224452-66-8
AbMole Bioscience	M2974	http://www.abmole.com/products/retapamulin.html
Achemtek	0102-014536	http://www.achemtek.com/224452-66-8
Ambeed	A195059	https://www.ambeed.com/products/224452-66-8.html
ApexBio Technology	B2019	http://www.apexbt.com/retapamulin.html
AstaTech, Inc.	36342	http://www.astatechinc.com/CPSResult.php?CRNO=36615
Aurora Fine Chemicals LLC	A13.110.966	http://online.aurorafinechemicals.com/info?ID=A13.110.966
Aurora Fine Chemicals LLC	A24.091.139	http://online.aurorafinechemicals.com/info?ID=A24.091.139
Aurum Pharmatech LLC	MP-0763	http://www.Aurumpharmatech.com/Product/ProductDetails/MP_0763
BLD Pharm	BD223980	http://www.bldpharm.com/products/224452-66-8.html
Boerchem	BC677692	http://www.boerchem.com/?product_39573.html
CSNpharm	CSN12909	https://www.csnpharm.com/products/retapamulin.html
Chem Scene	CS-0618	http://www.chemscene.com/224452-66-8.html
ChemMol	44009997	http://www.chemmol.com/chemmol/44009997.html
ChemMol	99062376	http://www.chemmol.com/chemmol/99062376.html
Chemspace	CSSB00020618600	https://chem-space.com/CSSB00020618600
Chemspace	CSSB00020629312	https://chem-space.com/CSSB00020629312
Combi-Blocks	QB-7392	http://www.combi-blocks.com/cgi-bin/find.cgi?QB-7392
Glentham Life Sciences	GA4340	http://www.glentham.com/products/product/GA4340/
Hairui	HR34097	http://www.hairuichem.com/en/product/224452-66-8.html
Lab Network	LN02127170	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN02127170
Matrix Scientific	98144	https://www.matrixscientific.com/098144.html
MedChem Express	HY-17010	https://www.medchemexpress.com/Retapamulin.html
MolPort	MolPort-006-167-754	https://www.molport.com/shop/molecule-link/MolPort-006-167-754
MolPort	MolPort-023-220-081	https://www.molport.com/shop/molecule-link/MolPort-023-220-081
MuseChem	A000673	https://www.musechem.com/product/A000673.html
OChem	25925	http://www.ocheminc.com/index.php?act=psearch&pid=452R668
Oakwood	361956	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=150814&ExtHyperLink=1
Renno Tech	RL02708	http://www.rennotech.com/product_show.asp?id=2957
Selleck Chemicals	S4056	http://www.selleckchem.com/products/retapamulin.html
Sigma-Aldrich	CDS023386_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/cds023386?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
TripleBond	CR0022	http://www.triplebond-canada.com/prod/1562/
Yuhao Chemical	LX2351	http://www.chemyuhao.com/224452-66-8.html
abcr GmbH	AB450172	http://www.abcr.com/shop/en/AB450172
eNovation Chemicals	D320205	https://www.enovationchem.com/ProductDetails.asp?ProductID=D320205
iChemical	EBD3585	http://www.ichemical.com/products/224452-66-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.	2006 Dec	17097398
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.	2006 Jul	16801451
Gateways to clinical trials.	2006 Oct	17136234
Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin.	2006 Sep-Oct	16957433
New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine.	2007 Jul-Aug	17616504
Gateways to clinical trials.	2007 Jun	17805439
Gateways to clinical trials.	2007 May	17609744
[Introduction to cutaneous bacterial infections].	2007 Sep	18093493
Altabax (retapamulin ointment), 1%.	2007 Sep-Oct	17786102
Current and novel antibiotics against resistant Gram-positive bacteria.	2008	21694878
Retapamulin (Altabax)--a new topical antibiotic.	2008 Feb 25	18292714
Clones and drones: do variants of Panton-Valentine leukocidin extend the reach of community-associated methicillin-resistant Staphylococcus aureus?	2008 Jan 15	18177251
Drug treatments for skin disease introduced in 2007.	2008 Mar	18373042
Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.	2008 May	18341664
Allergic contact cermatitis to retapamulin ointment.	2009 Aug	19706058
Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.	2009 Jul	19695409
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.	2010	21694898
The pleuromutilin antibiotics: a new class for human use.	2010 Feb	20112168
Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus.	2010 Oct	20941943

Patents

Sample Use Guides

In Vivo Use Guide

A thin layer of retapamulin (Altabax) should be applied to the affected area (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) twice daily for 5 days.

Route of Administration: Topical

In Vitro Use Guide

In vitro activity of retapamulin was determinde against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and linezolid and methicillin-resistant S. aureus (LR-MRSA). MSSA and MRSA isolates were susceptible to retapamulin, with an MIC90 of 0.094 mg/L and 0.125 mg/L respectively, but retapamulin MICs for the 18 LR-MRSA strains were over 32 mg/L in all cases.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:45:10 GMT 2023` Edited by `admin` on `Fri Dec 15 15:45:10 GMT 2023`
Record UNII	4MG6O8991R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RETAPAMULIN

Official Name

English

retapamulin [INN]

Common Name

English

RETAPAMULIN [MI]

Common Name

English

ALTABAX

Brand Name

English

RETAPAMULIN [EMA EPAR]

Common Name

English

SB275833

Code

English

RETAPAMULIN [MART.]

Common Name

English

(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-Ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl [[(1R,3S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl]acetate

Common Name

English

SB-275833

Code

English

RETAPAMULIN [ORANGE BOOK]

Common Name

English

RETAPAMULIN [USAN]

Common Name

English

RETAPAMULIN [VANDF]

Common Name

English

ALTARGO

Brand Name

English

Retapamulin [WHO-DD]

Common Name

English

ACETIC ACID, (((3-EXO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL)THIO)-, (3AS,4R,5S,6S,8R,9R,9AR,10R)-6-ETHENYLDECAHYDRO-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXO-3A,9-PROPANO-3AH-CYCLOPENTACYCLOOCTEN-8-YL ESTER

Common Name

English

NSC-759885

Code

English

Classification Tree Code System Code

WHO-ATC

D06AX13